Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas Featured Article: Boris P. Kovatchev, Eric.

Slides:

Advertisements

Similar presentations

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Advertisements

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.

Individual Mindfulness-Based Cognitive Therapy and Cognitive Behavior Therapy for Treating Depressive Symptoms in Patients With Diabetes: Results of a.

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Assessment of Patient-Led or Physician-Driven Continuous Glucose Monitoring in Patients With Poorly Controlled Type 1 Diabetes Using Basal-Bolus Insulin.

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.

An Automated Internet Behavioral Weight-Loss Program by Physician Referral: A Randomized Controlled Trial Featured Article: J. Graham Thomas, Tricia M.

Both Dietary Protein and Fat Increase Postprandial Glucose Excursions in Children With Type 1 Diabetes, and the Effect Is Additive Featured Article: Carmel.

Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.

The Patient Undergoing Surgery: Proven Steps to Better Outcomes Ariel U. Spencer, MD Lafayette Surgical Clinic Lafayette, Indiana.

Diabetes Technology Update

Closed-Loop Insulin Delivery in Children

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS

Journal Club 埼玉医科大学総合医療センター内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田昌文 Matsuda, Masafumi.

Artificial Pancreas Project at Cambridge R. Hovorka, J.M. Allen, L.J.Chassin, A. De Palma, D. Elleri, J. Harris, J.F. Hayes, T. Hovorka, K. Kumareswaran,

Feasibility of Outpatient Fully Integrated Closed-Loop Control First studies of wearable artificial pancreas Featured Article: Boris P. Kovatchev, Ph.D.,

Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.

Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial Featured Article: José Luis Lázaro-Martínez,

Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCOCABG Trial.

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Effectiveness of Early Intensive Therapy On β-Cell Preservation in Type 1 Diabetes Featured Article: Bruce Buckingham, M.D., Roy W. Beck, M.D., P.H.D.,

ABSTRACT Hyperglycaemia is prevalent in critical care, and tight control reduces mortality. Targeted glycaemic control can be achieved by frequent fitting.

Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free- Living, Randomized Clinical Trial Featured Article: Roman Hovorka,

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Michelle D. Stancil, RN, BSN, CDE Blix M. Rice, MBA, CHFP October 16, 2015 Putting a Diabetes Educator in Your Pocket: A Novel Approach to Disease Management.

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Meal Detection and Meal Size Estimation for Type 1 Diabetes: a Variable State Dimension Approach 2015 DSCC Columbus Oct. 30 Jinyu Xie, Prof. Qian Wang.

MPC for Type 1 Diabetes Based on Personalized LTV Model Consisting of both Insulin and Meal inputs Qian Wang, Jinyu Xie et al Background Modeling Control.

Intensive Versus Intermediate Glucose Control in Surgical Intensive Care Unit Patients Featured Article: Takehiro Okabayashi, Yasuo Shima,Tatsuaki Sumiyoshi,

Extra-Virgin Olive Oil Reduces Glycemic Response to a High–Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial Featured.

Date of download: 6/26/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Lauren M. Huyett, Eyal Dassau, and Francis J. Doyle III Department of Chemical Engineering University of California Santa Barbara Santa Barbara, CA

Progress Toward Artificial Pancreas (AP) Systems – A Timeline s 1980s : JDRF.

Nallasamy K, Jayashree M, Singhi S, Bansal A

2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial Dr.

Key publication slides

Neal B, et al. Diabetes Care 2015;38:403–411

Diabetic Dyslipidemia in Practice

Updates to Managing Diabetes in the Long-Term Care Setting

Figure 5 Risk factor control in the intensive treatment group

Predictive Low Glucose Suspend (PLGS)

Volume 375, Issue 9716, Pages (February 2010)

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Completed and ongoing CVOTs (6–14,39,44–58)

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Meal control achieved in the five meals of the study (the first dinner was handled in open-loop mode, and all other meals were handled by closed-loop).

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Distribution of daily frequency of BGM

Postoperative blood glucose levels and total insulin requirement.

Cumulative mean numbers of confirmed (plasma glucose ≤3

ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia.

Presentation transcript:

Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas Featured Article: Boris P. Kovatchev, Eric Renard, Claudio Cobelli, Howard C. Zisser, Patrick Keith-Hynes, Stacey M. Anderson, Sue A. Brown, Daniel R. Chernavvsky, Marc D. Breton, Lloyd B. Mize, Anne Farret, Jérôme Place, Daniela Bruttomesso, Simone Del Favero, Federico Boscari, Silvia Galasso, Angelo Avogaro, Lalo Magni, Federico Di Palma, Chiara Toffanin, Mirko Messori, Eyal Dassau, and Francis J. Doyle III Diabetes Care Volume 37: July, 2014

STUDY OBJECTIVE To estimate the effect size of hypoglycemia risk reduction on closed-loop control (CLC) versus open-loop (OL) sensor- augmented insulin pump therapy in a supervised outpatient setting Kovatchev B. P. et al. Diabetes Care 2014;37:

STUDY DESIGN AND METHODS 20 patients with type 1 diabetes initiated the study at the Universities of Virginia, Padova, and Montpellier and Sansum Diabetes Research Institute 18 completed the entire protocol Each patient participated in two 40-h outpatient sessions, CLC versus OL, in randomized order Sensor (Dexcom G4) and insulin pump (Tandem t:slim) were connected to Diabetes Assistant (DiAs) (a smartphone artificial pancreas platform) Kovatchev B. P. et al. Diabetes Care 2014;37:

STUDY DESIGN AND METHODS The patient operated the system through the DiAs user interface during both CLC and OL Study personnel supervised onsite and monitored DiAs remotely Kovatchev B. P. et al. Diabetes Care 2014;37:

RESULTS The primary outcome [reduction in risk for hypoglycemia as measured by the low blood glucose (BG) index (LGBI)] resulted in an effect size of 0.64 There was a twofold reduction of hypoglycemia requiring carbohydrate treatment: 1.2 vs. 2.4 episodes/session on CLC versus OL This result was accompanied by a slight decrease in percentage of time in the target range of 3.9–10 mmol/L and increase in mean BG on CLC versus OL Kovatchev B. P. et al. Diabetes Care 2014;37:

CONCLUSIONS CLC running on a smartphone (DiAs) in outpatient conditions reduced hypoglycemia and hypoglycemia treatments compared with sensor-augmented pump therapy Kovatchev B. P. et al. Diabetes Care 2014;37: